Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

By C. Herzog, R. Asinger, A. Berger, D. Charytan, J. Díez, R. Hart, Kai-Uwe Eckardt, B. Kasiske, P. McCullough, R. Passman and 3 more. Kidney International, 2011

922 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology

View Paper: https://www.semanticscholar.org/paper/1c38aba4ed09cad2bc2c71b1c59f1bca26963cad

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. A. Goette
2. A. Levin
3. A. Levey
4. Giuseppe Remuzzi

In Nephrology

1. A. Levey
2. Josef Coresh
3. Marcello Tonelli
4. Harold I. Feldman
5. A. Levin
6. R. Gansevoort
7. Giuseppe Remuzzi
8. R. Mehta

Citations in the corpus

• The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. (2018, background): “In fact, given the lack of strong evidence also for VKA in this patient population, the decision to anticoagulate remains a very individualized one requiring a multidisciplinary approach considering and respecting patients’ preferences.(180,208,213)”
• Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. (2017, background): “However, it is clear that other forms of CVD also have a major impact on morbidity and mortality in this population (see above).(137,138) The well-documented but poorly understood regional variations in CVD phenotype among CKD populations may offer new insights into how outcomes can be improved.”